Date:1/29/2009

Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufac
'/>"/>

SOURCE Repligen Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
2. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
3. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
4. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
5. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
6. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
7. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
9. Omnitura Therapeutics Announces Private Placement Financing
10. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast